Replies to post #15081 on ViaDerma Inc (VDRM)

[Mistral]

It's a Weak Buy according to Barchart. Forward sales projections are very dangerous with this company's antibiotic sales history.

The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

@ $125 = $62,500,000 coming in 2017! wow

We are a SCREAMING BUY here people!!